About ImmunoBiology
ImmunoBiology is a company based in Babraham (United Kingdom) founded in 2003 by Camilo Colaco. ImmunoBiology has raised $1.18 million across 4 funding rounds from investors including European Union. The company has 3 employees. ImmunoBiology operates in a competitive market with competitors including Insmed, VBI Vaccines, Affinivax, Imvax and Eligo Bioscience, among others.
- Headquarter Babraham, United Kingdom
- Employees 3
- Founders Camilo Colaco
- SectorsHealthcare
- Website immbio.net
- Social LinkedIn
- Legal Name Immunobiology Limited
- Date of Incorporation 26 May, 1999
- Jurisdiction CAMBRIDGE
- Annual Revenue$584.69 K (USD)0as on May 31, 2019
- Net Profit-$632.32 K (USD)-207as on May 31, 2020
- EBITDA-$748.68 K (USD)-93as on May 31, 2020
- Total Equity Funding$1.18M (USD)
in 4 rounds
- Latest Funding Round$193.26K (USD), Unspecified
Feb 2020
- Investors
- Employee Count3
Funding Insights of ImmunoBiology
ImmunoBiology has successfully raised a total of $1.18M across 4 strategic funding rounds. The most recent funding activity was a Unspecified round of $193.26 thousand completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.18M
- Total Rounds 4
- Last Round Unspecified — $193,260
- First Round $724,000
(Mar 2016)
- Investors Count 1
All 4 funding rounds of ImmunoBiology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $193,260 | Unspecified | – | – | – |
| May 2019 | $65,264 | Grant | – | – | |
| Mar 2019 | $262,566 | Unspecified | – | – | – |
| Mar 2016 | $724,000 | Unspecified | – | – | – |
1 investors in total: 1 institutional.
Investors in ImmunoBiology
ImmunoBiology has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ImmunoBiology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImmunoBiology
1 people are tracked at ImmunoBiology (1 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Camilo Colaco | Founder | Leadership |
Complete people profiles for ImmunoBiology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImmunoBiology
3 dated milestones of ImmunoBiology across 17 years, from founding to its latest funding, stage changes and deals.
- Founded ImmunoBiology is founded.
- Funding First funding round of $724K.
- Funding Latest funding round, Unspecified, of $193K.
Competitors of ImmunoBiology
ImmunoBiology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, VBI Vaccines, Affinivax, Imvax and Eligo Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| maatpharma.com | 2014 | Lyon, France | $42.3M | – | Microbiome therapies are developed for treating intestinal dysbiosis diseases. | |
| briacell.com | 2004 | Beverly Hills, United States | – | 16 | Developer of immunotherapies for the treatment of cancer |
Detailed competitors of ImmunoBiology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunobiology
Complete news archive for ImmunoBiology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ImmunoBiology
10 companies that operate in the same segment as ImmunoBiology (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ImmunoBiology
ImmunoBiology was founded in 2003 and raised its 1st funding round 13 years after it was founded.
ImmunoBiology is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
ImmunoBiology is a funded company, having raised a total of $1.18M across 4 funding rounds to date. The company's 1st funding round was a Unspecified of $724K, raised on Mar 2016.
ImmunoBiology has 3 employees.
Annual revenue of ImmunoBiology is $584.69K as on May 31, 2019.
The company was founded in 2003 in Babraham, United Kingdom, and operates in the biotechnology sector focused on vaccine development. Proprietary ImmBioVax platforms are utilized to target bacterial pathogens, addressing conditions such as pneumococcal disease, meningitis, and tuberculosis. Specific products include PnuBioVax for invasive pneumococcal disease, MenBioVax for meningococcal disease, T-BioVax for tuberculosis, along with candidates against Helicobacter pylori and Clostridium difficile.
ImmunoBiology's top competitors include Imvax, VBI Vaccines and Aridis Pharma.
ImmunoBiology has 1 investor. Key investors include European Union.
ImmunoBiology operates through Immunobiology Limited.